# NCT03834961 (NCT03834961)

> Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03834961
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Children's Oncology Group
- Conditions: Central Nervous System Neoplasm; Infantile Fibrosarcoma; Recurrent Acute Leukemia; Refractory Acute Leukemia; Solid Neoplasm
- Interventions: Larotrectinib Sulfate
- Enrollment: 33
- Primary outcome: Objective Response Rate (ORR) of Children With Infantile Fibrosarcoma (IFS) Treated With Neoadjuvant Larotrectinib Prior to Local Control

## Commentary we found

- YouTube: 5
- Podcasts: 3
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03834961

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03834961", "email": "<work email>"}; the inbox owner confirms by the emailed link.